Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach(RELATE)

NCT01003106 is registered in ClinicalTrials.gov with Peter A Campochiaro, MD as lead sponsor.

NCT NCT01003106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01003106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach(RELATE)
Lead sponsor
Peter A Campochiaro, MD
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2009
Completion date
April 30, 2015
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal vein occlusion